These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 19318995

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data.
    Santana-Davila R, Szabo A, Arce-Lara C, Williams CD, Kelley MJ, Whittle J.
    J Thorac Oncol; 2014 May; 9(5):702-9. PubMed ID: 24662458
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel.
    Edelman MJ, Clark JI, Chansky K, Albain K, Bhoopalam N, Weiss GR, Giguere JK, Kelly K, Crowley J, Gandara DR.
    Clin Cancer Res; 2004 Aug 01; 10(15):5022-6. PubMed ID: 15297403
    [Abstract] [Full Text] [Related]

  • 6. Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non--small-cell lung cancer.
    Gridelli C, Rossi A, Di Maio M, Leo S, Filipazzi V, Favaretto AG, Burgio MA, Cinieri S, Bianco R, Ciardiello F, Cavanna L, Bordonaro R, Costanzo R, Sandomenico C, Gallo C, Perrone F, Morabito A.
    Clin Lung Cancer; 2014 Mar 01; 15(2):166-70. PubMed ID: 24418693
    [Abstract] [Full Text] [Related]

  • 7. Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer.
    Syrigos KN, Vansteenkiste J, Parikh P, von Pawel J, Manegold C, Martins RG, Simms L, Sugarman KP, Visseren-Grul C, Scagliotti GV.
    Ann Oncol; 2010 Mar 01; 21(3):556-561. PubMed ID: 19828561
    [Abstract] [Full Text] [Related]

  • 8. Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study).
    Kreuter M, Vansteenkiste J, Fischer JR, Eberhardt WE, Zabeck H, Kollmeier J, Serke M, Frickhofen N, Reck M, Engel-Riedel W, Neumann S, Thomeer M, Schumann C, De Leyn P, Graeter T, Stamatis G, Griesinger F, Thomas M, TREAT investigators.
    J Thorac Oncol; 2016 Jan 01; 11(1):85-93. PubMed ID: 26762743
    [Abstract] [Full Text] [Related]

  • 9. Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): a combined analysis of three phase 3 trials.
    Treat J, Scagliotti GV, Peng G, Monberg MJ, Obasaju CK, Socinski MA.
    Lung Cancer; 2012 May 01; 76(2):222-7. PubMed ID: 22115704
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101).
    Comella P, Filippelli G, De Cataldis G, Massidda B, Frasci G, Maiorino L, Putzu C, Mancarella S, Palmeri S, Cioffi R, Roselli M, Buzzi F, Milia V, Gambardella A, Natale D, Bianco M, Ghiani M, Masullo P, Southern Italy Cooperative Oncology Group.
    Ann Oncol; 2007 Feb 01; 18(2):324-30. PubMed ID: 17071935
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).
    Kentepozidis N, Economopoulou P, Christofyllakis C, Chelis L, Polyzos A, Vardakis N, Koinis F, Vamvakas L, Katsaounis P, Kalbakis K, Nikolaou C, Georgoulias V, Kotsakis A.
    Clin Transl Oncol; 2017 Mar 01; 19(3):317-325. PubMed ID: 27492015
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis.
    Kang EJ, Min KH, Hur GY, Lee SY, Shim JJ, Kang KH, Oh SC, Seo JH, Kim JS.
    Chemotherapy; 2016 Mar 01; 61(1):41-50. PubMed ID: 26517706
    [Abstract] [Full Text] [Related]

  • 17. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale.
    Gebbia V, Galetta D, Caruso M, Verderame F, Pezzella G, Valdesi M, Borsellino N, Pandolfo G, Durini E, Rinaldi M, Loizzi M, Gebbia N, Valenza R, Tirrito ML, Varvara F, Colucci G, Gruppo Ocologico Italia Meridionale.
    Lung Cancer; 2003 Feb 01; 39(2):179-89. PubMed ID: 12581571
    [Abstract] [Full Text] [Related]

  • 18. Triplet platinum-based combination sequential chemotherapy improves survival outcome and quality of life of advanced non-small cell lung cancer patients.
    Chen LK, Liang Y, Yang QY, Xu F, Zhou NN, Xu GC, Liu GZ, Wei WD.
    Asian Pac J Cancer Prev; 2012 Feb 01; 13(5):1863-7. PubMed ID: 22901137
    [Abstract] [Full Text] [Related]

  • 19. [Gemcitabine plus cisplatin versus gemcitabine plus vinorelbine in treatment of advanced non-small cell lung cancer (NSCLC)].
    Zhang L, Zhang Y, Li N, Xu F, Pan ZK, Guan ZZ.
    Ai Zheng; 2004 Nov 01; 23(11 Suppl):1455-8. PubMed ID: 15566656
    [Abstract] [Full Text] [Related]

  • 20. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer.
    Scagliotti G, Brodowicz T, Shepherd FA, Zielinski C, Vansteenkiste J, Manegold C, Simms L, Fossella F, Sugarman K, Belani CP.
    J Thorac Oncol; 2011 Jan 01; 6(1):64-70. PubMed ID: 21119545
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.